Please try another search
For the three months ended 31 March 2020, Exalenz Bioscience Ltd. revenues increased 1% to $3.4M. Net loss increased 13% to $752K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Expenses increase from $0K to $414K (expense), Research & Development increase of 2% to $724K (expense).
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 3.4 | 3.77 | 3.09 | 3.81 |
Gross Profit | 1.67 | 1.8 | 1.67 | 1.76 |
Operating Income | -0.58 | 0.07 | -0.07 | 0.1 |
Net Income | -0.75 | -0.38 | -0.67 | -0.22 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 13.8 | 12.62 | 12.59 | 11.87 |
Total Liabilities | 18.88 | 17.01 | 16.7 | 15.45 |
Total Equity | -5.08 | -4.39 | -4.11 | -3.57 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -0.34 | 1.6 | 0.69 | 0.34 |
Cash From Investing Activities | -0.02 | -0.18 | -0.07 | -0.05 |
Cash From Financing Activities | -0.27 | -0.14 | -0.06 | -0.75 |
Net Change in Cash | -0.61 | 1.24 | 0.55 | -0.43 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review